NCT06841692Recruiting
Diuretic Testing in Chronic Kidney Disease
Source: ClinicalTrials.gov · Last updated 7 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to predict the progression of chronic kidney disease by diuretic testing in patients with chronic kidney disease. The main questions it aims to answer are: Does a worse result of a diuretic test predict the progression of chronic kidney disease? If there is a comparison group: Researchers will compare the diuretic test in patients with chronic kidney disease to healthy participants to see if the results are different in a healthy kidney. Participants will undergo diuretic testing. This involves the administration of bumetanide and hydrochlorothiazide with subsequent blood and urine collections.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 86 (estimated)
- First submitted
- 18 Feb 2025
- Start date
- 1 Apr 2025
- Primary completion date
- 31 Oct 2029
- Lead sponsor
- Erasmus Medical Center
- Diseases
- Chronic kidney disease
- NCT number
- NCT06841692
What you commit to
- Study type: Interventional
- Planned participants: 86
- From 1 Apr 2025 to the primary completion date, 31 Oct 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Kidney transplant recipient
- Use of calcineurin-inhibitors
- Current treatment with inhibitors of Organic anion transporters: probenecid, pravastatin, cimetidine, cephalosporins, acetazolamide \[22\]
- Active drug- or alcohol abuse
- Not being able to tolerate a 28-day washout of one of the drugs interfering with diuretic testing.
Other illness
- Known intolerance or allergy to the diuretics
- Current systemic chemotherapy for malignancy
- Autosomal dominant polycystic or tubulointerstitial kidney disease causing CKD
- Clinically relevant heart failure (New York Heart Association class III or IV)
- Therapy-resistant hypertension, defined as systolic blood pressure \> 180mmHg at the inclusion visit
- Active hepatitis during last outpatient visit
Lab values
- Hypokalemia or hyperkalemia (K+ \< 3.0mmol/L or K+ \> 5.5 mmol/L) at inclusion visit
- Hypo- or hypernatremia (Na+ \< 130 mmol/L or Na+ \> 150mmol/L) at inclusion visit
Other
- Life expectancy \< 12 months
- Current immunosuppressive treatment for glomerulonephritis
- Incapacitated subjects or subjects who are deemed unfit to adequately adhere to instructions from the research team
- Inherited tubulopathy as the cause of CKD
- Liver cirrhosis in advanced stage (Child-Pugh B or C)
- Women who are pregnant, breastfeeding, or planning on becoming pregnant before the test day
Who the study is looking for
- CKD stage G3 (creatinine-based eGFR 30-59 mL/min/1.73m2) during the last outpatient visit
- eGFR within the expected range for age (a decline of 1 ml/min/1.73 m2 per year starting from age 40 is considered the normal age-related decline in kidney function
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Erasmus MC Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.